Sumarriva Gonzalo, Habashy Alexander, Saxena Tara, Chimento George
Department of Orthopedic Surgery, Ochsner Clinic Foundation, New Orleans, LA.
The University of Queensland Faculty of Medicine, Ochsner Clinic Foundation, New Orleans, LA.
Ochsner J. 2021 Winter;21(4):347-351. doi: 10.31486/toj.20.0169.
Postoperative total joint arthroplasty complications place a tremendous burden on the health care system. The purpose of this study was to compare 30-day postoperative complication rates for surgeries in patients who received preoperative antiplatelet agents and/or anticoagulants to surgeries in a control group that did not receive antiplatelet agents and/or anticoagulants in the 90 days prior to undergoing a total joint arthroplasty. We retrospectively reviewed total hip or knee arthroplasties from November 2012 to March 2016. Surgeries were categorized into 4 groups depending on their preoperative antiplatelet and anticoagulant status. Complications between the groups were compared using chi-square analysis and Fisher exact test. In this study, 1,726 arthroplasties in 1,544 patients were included. Superficial wound complications were the most common complication in all 4 groups (3.8% of surgeries), with no significant difference between the groups. A statistically significant difference was found in the number of prosthetic joint infections in the group of surgeries with no antiplatelets or anticoagulants compared to surgeries with both medications administered during the 90 days preoperatively (0.82% vs 5.13%, =0.0003). No significant difference was found between the groups with regard to stroke, myocardial infarction, pulmonary embolism, or deep venous thrombosis. Surgeries for which both antiplatelets and anticoagulants were administered in the 90 days preoperatively had a statistically significantly higher rate of prosthetic joint infections compared to surgeries with neither medication administered preoperatively. Surgeons can use this information to better inform and risk-stratify patients prior to surgery.
全关节置换术后并发症给医疗保健系统带来了巨大负担。本研究的目的是比较接受术前抗血小板药物和/或抗凝剂治疗的患者手术与未在全关节置换术前90天接受抗血小板药物和/或抗凝剂治疗的对照组手术的术后30天并发症发生率。我们回顾性分析了2012年11月至2016年3月期间的全髋关节或膝关节置换术。根据术前抗血小板和抗凝状态,手术分为4组。采用卡方分析和Fisher精确检验比较各组之间的并发症。本研究纳入了1544例患者的1726例关节置换术。浅表伤口并发症是所有4组中最常见的并发症(占手术的3.8%),各组之间无显著差异。与术前90天同时使用两种药物的手术相比,未使用抗血小板或抗凝剂的手术组中假体关节感染的数量存在统计学显著差异(0.82%对5.13%,P=0.0003)。在中风、心肌梗死、肺栓塞或深静脉血栓形成方面,各组之间未发现显著差异。与术前未使用任何药物的手术相比,术前90天同时使用抗血小板和抗凝剂的手术假体关节感染率在统计学上显著更高。外科医生可以利用这些信息在手术前更好地告知患者并进行风险分层。